Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Exelon To Be Reviewed By Advisory Cmte. May 17

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is seeking approval for rivastigmine tartrate for the treatment of mild to moderate dementia associated with Parkinson's disease.

You may also be interested in...



Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says

FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.

Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says

FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.

Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition

Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel